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Abstract
 
Human histocompatibility leukocyte antigen (HLA)-DM is a major histocompatibility com-
plex (MHC)-like protein that catalyzes exchange of antigenic peptides from MHC class II mol-
ecules. To investigate the molecular details of this catalysis we created four covalent complexes
between HLA-DM and the MHC class II allele DR1. We introduced a disulfide bond be-
tween the naturally occurring cysteine 
 
 
 
46 on HLA-DM and an engineered cysteine on the
end of a linker attached to either the NH
 
2
 
- or the COOH terminus of an antigenic peptide
that is tightly bound on DR1. We find that when DM is attached to the NH
 
2
 
 terminus of the
peptide, it can, for all linker lengths tested, catalyze exchange of the peptide with a half-life a
few minutes (compared with uncatalyzed t
 
1/2 
 
  
 
100 h). This rate, which is several orders of
magnitude greater than the one we obtain in solution assays using micromolar concentrations
of HLA-DM, is dominated by a concentration independent factor, indicating an intramolecular
catalytic interaction within the complex. A similar complex formed at the COOH terminus of
the peptide shows no sign of DM-specific intramolecular catalysis. Restrictions on the possible
 
interaction sites imposed by the length of the linkers indicate that the face of DR1 that accommo-
dates the NH
 
2
 
 terminus of the antigenic peptide interacts with the lateral face of HLA-DM that
contains cysteine 
 
 
 
46.
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Introduction
 
Newly synthesized major histocompatibility complex class
II molecules contain in their peptide binding groove a por-
tion of the invariant chain I
 
i
 
 (1). The I
 
i
 
 segment must then
be exchanged with antigenic peptides destined for presen-
tation on the cell surface (2). This exchange occurs in spe-
cialized endosomal compartments and is facilitated by a
nonclassical MHC class II molecule named HLA-DM
(3–5) (henceforth denoted as DM).
 
*
 
 Peptide exchange
from MHC class II molecules is very slow and inefficient in
the absence of DM, both in vivo and in vitro (6–9). Accel-
eration of this exchange by DM follows Michaelis-Menten
kinetics, and is proportional to the intrinsic rate of peptide
 
dissociation (10). The structure of DM, determined by
x-ray crystallography (11, 12), shows a fold similar to that
of classical MHC class II molecules, but with the striking
absence of a peptide binding groove. The structure pro-
vides no clear answers to the mechanism of catalysis, how-
ever. Recent biochemical and kinetic evidence impli-
cate a previously suggested alternative conformation of
the MHC molecule that is an intermediate in the peptide
loading pathway and can exchange peptide rapidly (13,
14). It has been proposed that DM may act either by stabi-
lizing this intermediate MHC conformation (15) or by ac-
celerating the interconversion of the stable MHC state to
this conformation (16). Nevertheless, virtually nothing is
known at a molecular level about the interaction of DM
 
Address correspondence to E. Stratikos, Department of Cellular and Mo-
lecular Biology, Howard Hughes Medical Institute, Harvard University,
 
Cambridge, MA 02138. Phone: 617-495-1808; Fax: 617-495-9613; E-mail:
Stratikos@crystal.harvard.edu
 
*
 
Abbreviations used in this paper:
 
 DM, HLA-DM; DR1, HLA-DR1. 
174
 
Lateral Interaction Surfaces of HLA-DM with HLA-DR1
 
with MHC molecules or any related conformational
changes.
Both DM and HLA-DR1 (a class II MHC molecule,
henceforth denoted as DR1) are heterodimers with each
chain contributing about half of the total molecular weight
of the protein. Each chain has a large extracellular region, a
single transmembrane segment, and a small cytoplasmic do-
main. Full-length, B cell–derived, detergent-solubilized
DM stimulates in vitro peptide exchange from full-length
HLA-DR class II molecules (5, 8). Nanomolar concentra-
tions of DM are sufficient to achieve physiologically rele-
vant rates of exchange in these experiments. By contrast,
micromolar concentrations of soluble recombinant DM
(lacking the transmembrane segment and cytoplasmic tail)
are needed to obtain a similar exchange rate on soluble DR
(4). The difference in rates has been attributed to the effect
of colocalization of full-length DM and DR on detergent
micelles or lipid bilayers and not to specific interactions of
the transmembrane or cytoplasmic domains of the two pro-
teins (17). Indeed, theoretical calculations of the effect of
anchoring interacting proteins on lipid bilayers estimate an
enhancement of up to 10
 
6
 
-fold in their interactions, due to
high local concentrations, excluded volume by other pro-
teins and entropic effects (18).
To investigate the DR1/DM interaction in the absence
of the lipid bilayer or detergent micelles we created a series
of tethered complexes and screened for the ability of DM
to catalyze peptide exchange within each complex. Screen-
ing for productive interaction as a function of attachment
position and tether length in DM/DR1 complexes pro-
vides an opportunity to investigate the general structural
features of the interaction and to identify surfaces in each
molecule that contact each other during catalysis. The
tether (linker) was in all cases attached to cysteine 
 
 
 
46 of
DM, which is located on a conserved surface patch of the
molecule, and which is therefore a candidate for interaction
with DR1. Although this area of DM is not the only one
conserved between different species, screening of different
linker lengths can be used to investigate whether the site of
interaction on DM is located proximally or distally to the
attachment point of the tether. Two linkage sites were ex-
plored on DR1: the NH
 
2
 
 terminus and the COOH termi-
nus of the bound peptide. These two sites are located on
opposite faces of DR1 and therefore allow us to determine
which is the lateral face of DR1 that interacts with DM.
We have constructed a series of covalently linked soluble
DM/soluble DR complexes by introducing a disulfide
bond between the naturally occurring cysteine 
 
 
 
46 of DM
and a cysteine introduced on the peptide bound to DR1.
We show that in complexes in which DM is linked
through the NH
 
2
 
 terminus of the peptide, catalytic activity
is retained and peptide dissociation is very rapid, presum-
ably because of the high concentration of DM in the vicin-
ity of DR1 as induced by the covalent linkage. Cross-link-
ing thus simulates, in the absence of detergents and full
length molecules, the high local concentrations induced by
anchoring the proteins on a lipid bilayer. Variation of the
linker length has only minimal effects on catalysis, indicat-
 
ing saturation of the catalytic capacity of DM in these com-
plexes. No catalytic effect was found when DM was at-
tached to the DR/peptide complex through the COOH
terminus of the peptide, indicating that DM interacts with
the lateral face of DR1 that is adjacent to the NH
 
2
 
 terminus
of the bound peptide, in agreement with previously pub-
lished mutational data (7, 19). When DM is attached to the
NH
 
2
 
 terminus of the peptide its catalytic ability is retained
even for linkers as small as 3 amino acids, indicating that
DR1 contacts the lateral face of DM to which the linker is
attached (on cysteine 
 
 
 
46).
 
Materials and Methods
 
Expression and Purification of Proteins.
 
Recombinant HLA-DR1
was produced and purified as previously described (4, 20). Briefly,
HLA-DR1 was secreted from a stably transfected Schneider 2 in-
sect cell line. Expression was induced by 1 mM CuSO
 
4
 
, and the
cell supernatant was collected after 4–5 d. The supernatant was
cleared by centrifugation and loaded onto a LB 3.1 antibody col-
umn, washed with PBS, and eluted with CHAPS at pH 11.5.
The fractions were immediately neutralized with Tris buffer at
pH 8, concentrated, and the buffer was exchanged with PBS. For
peptide loading, 1 mM PMSF, 1 mM EDTA, 0.02% NaN
 
3
 
, and a
20-fold excess of peptide were added to the protein, and the mix-
ture was filter sterilized and incubated at 37
 
 
 
C for 72 h. The pep-
tide-loaded DR1 was further purified on a Sepharose S200 size
exclusion column (Amersham Pharmacia Biotech), concentrated
to 2–10 mg/ml, and stored at 4
 
 
 
C for a few days or at –80
 
 
 
C for
longer periods of time.
Recombinant HLA-DM was also expressed in a stably trans-
fected S2 insect cell line as described previously (11) and purified
by size exclusion chromatography (Sepharose S200; Amersham
Pharmacia Biotech) and anion exchange chromatography (MonoQ;
Amersham Pharmacia Biotech). The protein was typically stored
in aliquots at –80
 
 
 
C, but it was found to be stable at 4
 
 
 
C for sev-
eral weeks.
 
Peptide Synthesis and Activation.
 
All peptides used in this study
are modifications of the highly antigenic hemagglutinin peptide
HA (sequence: PKYVKQNTLKLAT) modified at the NH
 
2
 
- or
COOH terminus with linker extensions bearing a single cysteine
residue near the end of the linker (see Table I). The linker exten-
sions were not found to affect the ability of the peptides to bind
DR1, or the stability of DR1-peptide complexes as judged by
SDS-PAGE (data not shown). Peptides synthesized by solid-
phase Fmoc chemistry were deprotected, purified by reverse-
phase HPLC, and analyzed by electrospray mass spectrometry to
confirm purity and integrity. Peptide concentrations were deter-
mined by absorption at 280 nm, using an extinction coefficient of
1,215 M
 
 
 
1
 
cm
 
 
 
1
 
. As the single cysteine residue on each peptide
was prone to oxidation, the purified peptides were dissolved in
Tris buffer, pH 8.0, to a final concentration of 
 
 
 
1 mM, and re-
acted with a twofold excess of dithiothreitol (DTT) for 30 min at
room temperature. 
 
5,5
 
 
 
-
 
Dithiobis(2-nitrobenzoic acid)
 
 (
 
DTNB)
was added in a fourfold excess over DTT and allowed to react for
30 min at room temperature to yield the peptide–TNB adduct.
The peptide–TNB adduct was purified on a Superdex Peptide
HR 10/30 size exclusion column (Amersham Pharmacia Bio-
tech) and kept at –80
 
 
 
C until needed.
 
Construction of DM–Peptide Adduct.
 
Purified DM was found
to contain 0.1 to 0.5 free cysteines per mol protein, depending on
the preparation, possibly because the naturally occurring cysteine 
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at position 46
 
 
 
 was partially oxidized and blocked by a small
molecule. Treatment of DM with 1–2 mM DTT for 1 h at room
temperature followed by repurification by size-exclusion chroma-
tography to separate the excess DTT, yielded protein that con-
tained 0.8–0.9 free cysteines per mol protein and had activity
comparable to the untreated protein (data not shown). The
DTT-treated DM was stable for weeks at 4
 
 
 
C with cysteine 
 
 
 
46
remaining reduced. The DM–peptide conjugate was made by
mixing the DTT-treated DM with a 10-fold excess peptide–
TNB adduct and allowing them to react for 2 h at room temper-
ature. The progress of the reaction could be followed by native
gel electrophoresis, because the peptide has a net charge of 
 
 
 
3
and thus imparts a lower electrophoretic mobility to DM when it
is linked on it. The yield of this reaction varied from 50–80%.
The product, DM–peptide adduct, was purified on size exclusion
chromatography (Sephadex Peptide; Amersham Pharmacia Bio-
tech) to separate any free peptide that would interfere with later
steps. The DM–peptide adduct was found to be able to fully sub-
stitute for DM in the catalysis of CLIP peptide exchange of DR1
using the fluorescence polarization assay described below (data
not shown) indicating that the derivatization of cysteine 46
 
 
 
 with
a peptide did not affect DM activity.
It is possible to construct the DM–peptide–DR complex by
mixing the DM–peptide adduct either with empty DR1 pro-
duced in insect cells or with DR1 complexed with a weakly
binding peptide. Because of limitations in the amount of DM–
peptide adduct that could be made, we found it more efficient to
preload DR1 with a readily available weakly binding peptide and
then exchange it out with DM–peptide. Therefore, a two step
strategy was adopted that exploited the low affinity for DR1 in
the presence of streptavidin of an NH
 
2
 
-terminally truncated and
biotinylated HA peptide, bYHA (see Table I). This peptide can
be loaded with high yield onto insect expressed DR1, but can be
exchanged-out easily if it is complexed with streptavidin through
its biotin moiety. This induced weak affinity was exploited for
the construction of the DM–peptide–DR complex with high
yields. bYHA–DR1 complex was mixed with a 2–4 molar excess
of streptavidin and a 2–3-fold excess of DM–peptide adduct. Af-
ter overnight incubation, the mixture was separated on a sepha-
rose S200 size exclusion column; SDS-PAGE electrophoresis
confirmed that the largest peak (at around 90 kD) was the DM–
peptide–DR complex. In most cases the complex was further pu-
rified on a MonoQ column (Amersham Pharmacia Biotech)
eluted with a 0.025 to 0.5M NaCl gradient at pH 7.5.
 
Measurement of Complex Dissociation.
 
To measure the effect of
the proximity of DM and DR1 in all complexes constructed, we
devised a simple kinetic assay. Purified complex (1–20 
 
 
 
M) was
mixed with a large excess of HA peptide (2 mM) and the mixture
incubated at pH 5.0 at 37
 
 
 
C. At specific time intervals small ali-
quots of the reaction mixture were withdrawn, diluted 1:10,
mixed with native gel electrophoresis sample buffer, and immedi-
ately frozen on dry ice. All aliquots were kept frozen until they
were analyzed by native gel electrophoresis on a 10% polyacryl-
amide gel. The amount of complex that had dissociated at each
time point was estimated by densitometry of the band corre-
sponding to the complex on the gel, after staining with Coo-
massie Blue. The density of the band at each time point was cor-
rected for the gel background and divided by the density of a
control band of undissociated complex, to normalize to the frac-
tion of complex remaining. The normalized value was plotted
versus time. The data were fit using a single exponential decay
model: Y 
 
  
 
Span
 
*
 
exp(
 
 
 
K
 
*
 
X) 
 
 
 
 Plateau, which produced the
time constant K for the decay of the complex in the presence of a
large excess of free peptide HA. The half-life of the dissociation is
given by t
 
1/2
 
   
 
ln(2)/K, where ln(2) is the natural logarithm of 2.
Each measurement was repeated 3–5 times to allow calculation of
standard errors.
 
Construction of the Streptavidin/HA/DR1 Complexes.
 
Biotinyl-
ated versions of the HA peptide (see Table I) were constructed by
either reacting the NH
 
2
 
 terminus of the peptide with biotin-X
succinimidyl ester (Molecular Probes) before deprotection (for
construction of the bHA peptide) or with biotin-X-maleamide
(Molecular Probes) after deprotection (for the b6GHA and
HA6Gb peptides). In both cases the biotinylated peptides were
purified by reverse-phase HPLC and their correctness confirmed
by electro-spray mass spectrometry. 100-fold excess of each pep-
tide was mixed with purified insect DR1 and incubated at 37
 
 
 
C
for 3 d to load the peptide onto DR1. The DR1/peptide com-
plex was further purified by size exclusion chromatography. All
streptavidin/HA/DR1 complexes were constructed in situ by
mixing a 2:1 molar ratio of streptavidin (Molecular Probes) with
the appropriate DR1/peptide complex. The formation of the
complexes was confirmed by native PAGE by the appearance of
slower migrating bands compared with DR1/peptide, streptavi-
din, or streptavidin/peptide controls (not shown). The dissocia-
tion of these complexes upon the addition of excess HA peptide
was studied in a manner identical to the dissociation experiments
for DM/DR1 complexes described above, with only the slowest
migrating band being taken to be representative of the streptavi-
din/DR1 complex.
 
Measurement of Peptide Dissociation from DR1.
 
Peptide dissoci-
ation from DR1 was measured by ELISA using peptides carrying
a biotin moiety covalently linked to their NH
 
2
 
-termini by a 6
carbon linker. The biotin linker was attached before deprotection
by reacting with biotin-X succinimidyl ester (Molecular Probes).
The biotinylated peptide was loaded onto insect-produced DR1
as described above, and the complex was purified. Its dissociation
was followed by incubating the purified DR1/peptide with a 100
to 1,000-fold excess unbiotinlyated peptide at pH 5.0 and at
37
 
 
 
C in the presence of different concentrations of DM. At spe-
cific time points, a small aliquot was extracted from the reaction
mixture, diluted in ELISA dilution buffer (PBS with 0.3% BSA)
and frozen. After the end of the time course all aliquots were
thawed and loaded on an ELISA plate coated with the LB3.1 an-
tibody, and allowed to bind for 1 h at 4
 
 
 
C. The plate was washed
three times with PBST (15 min each wash) and streptavidin con-
jugated with horseradish peroxidase was added and allowed to
bind for 1 h at 4
 
 
 
C. The plate was washed five times with PBST,
and ABTS was added for detection. The developed color was
measured using a ELISA plate reader with a filter at 495 nm. The
data were plotted as signal versus time and fit to a single expo-
nential decay model to extract the observed rate of dissociation.
The observed rates were plotted versus DM concentration and fit
to a linear model.
For the measurement of the catalytic activity of DM when
tethered onto the COOH terminus of the HA peptide that was
bound onto DR1, a fluorescence polarization assay way used, as
the DR1 attached on DM would interfere with the ELISA assay
described above. Either the CLIP or the HA peptide were syn-
thesized with a cysteine residue at position P5 (peptides CLIP-
P5C and HA-P5C in Table I) and labeled with Alexa-C5-malea-
mide (Molecular Probes) by mixing an equimolar amount of the
peptide and the reagent in PBS and incubating for 30 min at
room temperature. The labeled peptides were purified on a re-
verse-phase C18 column and the products of the reaction con-
firmed by electro-spray mass spectrometry. The peptides were 
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loaded onto purified insect cell DR1 by addition of a 100-fold
excess of the peptide, incubating at 37
 
 
 
C for 3 d and purifying
the DR1/labeled peptide by size-exclusion chromatography. 10
nM of DR1 loaded with the labeled peptide were incubated in
the presence of 1 mM HA peptide at pH 5.0 with varying con-
centrations of DM, or with the DM/DR1 complex where DM is
tethered to the COOH terminus of the peptide and the fluores-
cence polarization signal of the mixture was followed over time
(excitation was at 490 nm and emission at 520 nm) using an Ana-
lyst AD (LJL Biosystems) plate reader. Upon incubation with un-
labeled peptide the labeled peptide is competed out of the DR1
binding site leading to a decrease of its fluorescence polarization
signal. Peptide exchange kinetics followed by this method were
found to be essentially identical to results obtained with the
ELISA method described above.
 
Results
 
Assembly of the DM–Peptide/DR1 Complex.
 
A series of
four covalent complexes between DM and peptide-loaded
DR1 was assembled by forming a disulfide bond between a
cysteine at the NH
 
2
 
 or COOH terminus of the HA peptide
and the naturally occurring cysteine 
 
 
 
46 on DM. This
DM–peptide adduct was then loaded onto DR1. DR1
molecules secreted from insect cells are free of tightly
bound antigenic peptides and can easily be loaded with
peptide by prolonged incubation (2–3 d) at 37
 
 
 
C (21). Al-
though it is possible to load the DM–peptide adduct onto
DR1 in this way (Fig. 1 A, last lane), the process requires
an excess of the peptide for satisfactory yield. Because the
amount of peptide is limited in our case by the amount of
the covalently attached DM, we adopted a strategy in
which DR1 is preloaded with a weakly bound peptide that
can be exchanged out by the DM–peptide adduct. In order
for such a competition to be effective, the affinity of DM–
peptide must be higher than the affinity of the preloaded
peptide. The CLIP peptide (PVSKMRMATPLLMQA)
has been reported to bind DR1 with an affinity lower than
the HA peptide (22) and free HA peptide will exchange
DR1-bound CLIP peptide with high yield. The exchange
of CLIP for DM-HA gave poor yields of DM–peptide/
DR1 complex, however, even after a 3-d incubation (Fig.
1 A, lane 4). Thus, it appears that the affinity of DM-HA
for DR1 is lower than the affinity of HA for DR1 and pos-
sibly even lower than the affinity of CLIP for DR1. Co-
valently attached DM to the HA peptide must therefore
catalyze the peptide dissociation very efficiently, presum-
ably because of the high effective concentration induced by
the linkage, thus inducing an observed lower affinity for
the attached peptide.
The DM–peptide adduct can be loaded onto DR1 with
high yield by exploiting the observed reduction of affinity
of the truncated and biotinylated bYHA peptide (Table I)
in the presence of streptavidin. DR1 can be loaded with
high yield with the bYHA peptide, forming a stable com-
plex from which the peptide exchanges slowly (Fig. 1 B,
compare lanes 2 and 4 and lanes 2 and 6 and 7). In the
presence of streptavidin, however, the resulting streptavi-
din/biotin-YHA/DR1 complex dissociates rapidly in the
 
presence of free peptide (Fig. 1 B, compare lanes 2 and 5).
We speculate that this rate enhancement is due to effects on
k
 
on
 
 and possibly on k
 
off
 
, because of steric hindrance from
the bulky streptavidin (MW 60,000 Da) attached to the bi-
otin near the peptide P1 side-chain. Mixing of the strepta-
vidin/biotin-YHA/DR1 complex with the DM–peptide
adduct, gave DM–peptide/DR1 in high yield (Fig. 1 C,
compare lanes 2 and 6 and 7). This technique can be used
effectively for the high yield loading of any weakly binding
peptide that is not in large supply.
A summary of the reaction steps used to assemble the
DM–peptide/DR1 complex is shown in Fig. 2. In the first
step the cysteine-containing HA peptide (usually oxidized
upon storage) was reduced by DTT and modified by
Figure 1. Analysis of different methods of assembly of DM–peptide/
DR1 complexes by native PAGE. (A) DM–peptide/DR1 complex can
be assembled either by loading of DM–peptide onto insect cell produced
empty DR1 or by competing out a preloaded CLIP peptide. DM–pep-
tide adduct was mixed either with purified DR1-CLIP or with insect cell
produced unloaded DR1, and incubated for 3 d at 25 C. The samples
were analyzed on 10% native PAGE. Lane 1, DM; lane 2, DR1/CLIP;
lane 3, DM–peptide adduct; lane 4, DM–peptide/DR1-CLIP mixture af-
ter incubation; lane 5, DM–peptide/insect DR1 mixture after incubation.
(B) Exchange of bYHA peptide bound on DR1 by free HA peptide is ac-
celerated by the binding of streptavidin. Lane 1, streptavidin; lane 2,
DR1/bYHA; lane 3, streptavidin mixed with DR1/bYHA; lane 4,
DR1/bYHA mixed with HA peptide; lane 5, streptavidin and HA pep-
tide mixed with DR1/bYHA; lanes 6 and 7, DR1/bYHA mixed with
HA and incubated at 37 C for 1 h; lane 8, DR1/HA. (C) The DM–pep-
tide/DR1 complex can be assembled with high yield by competing out
prebound bYHA peptide on DR1 with the aid of streptavidin. DR1
loaded with the bYHA peptide was mixed with a twofold excess strepta-
vidin and a 1.5-fold excess DM–peptide adduct. The sample was split in
two and was either incubated for 10 min or 24 h at 25 C. Lane 1, DM–
peptide; lane 2, DR1/bYHA; lane 3, DM–peptide (different preparation);
lane 4, DM; lane 5, purified DM–peptide/DR1 complex; lane 6, mixture
after 10 min incubation; lane 7, mixture after 24 h incubation. 
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DTNB to protect and activate the cysteine. Cysteine 
 
 
 
46
on DM was also found to be partially or totally oxidized
depending on the preparation, but when reduced by DTT
and repurified by size exclusion chromatography it re-
mained reduced during storage at 4
 
 
 
C (based on standard
DNTB assays; reference 23, and data not shown). Reac-
tion of the reduced DM with the TNB activated peptide
yielded the DM–peptide adduct with high yield (step 2) as
judged by native gel electrophoresis (Fig. 1 C, compare
lanes 1 and 4). Insect cell–secreted DR1 was loaded with
b-YHA peptide, purified, and mixed with streptavidin
(step 3) just before the final reaction. The DM–peptide
adduct was mixed with the streptavidin/b-YHA/DR1
complex, yielding the DM–petide/DR1 complex (step 4)
 
which could be purified away from streptavidin and unre-
acted DM–peptide by size exclusion chromatography
where it runs at 
 
 
 
90 kD (Fig. 3, peak 1). Typical yields of
the reaction were over 90% as judged by the obvious ab-
sence of DR1 running as a monomer (
 
 
 
50–60 kD) in
size-exclusion chromatograms of the mixture (Fig. 3, peak
2 and lane 6). The contents of the complex were con-
firmed by SDS-PAGE and shown to include both DM
and DR1 in an apparent 1:1 ratio (Fig. 3, lane 5, and inset
in chromatogram).
 
Peptide Dissociation in DM–Peptide/DR1 Complexes.
 
The
kinetics of the dissociation of DM–peptide/DR1 com-
plexes can be followed by native gel electrophoresis. Disso-
ciation of the complex in this case indicates dissociation of
the peptide since the peptide is covalently attached to DM.
Reaction with excess free peptide pushes the equilibrium
toward the dissociated complex and allows measurement of
the dissociation rate of the peptide attached to DM
(Scheme I):
Gels showing dissociation of DM–peptide/DR1 com-
plexes, as well as for streptavidin/biotin-peptide/DR1
complexes, are shown in Fig. 4. The DM–peptide/DR1
complex and the streptavidin/biotin–peptide/DR1 run as
the lowest mobility band on a native gel compared with
DM-peptide or DR1, and this band slowly disappears
upon incubation with a large excess of free HA peptide.
Different complexes show different dissociation kinetics.
The complexes with DM attached to the NH
 
2
 
 terminus of
the peptide (Fig. 4, A–D) have rapid dissociation kinetics
(half-lives of 10–40 min); the complex with DM attached
to the COOH terminus of the peptide (Fig. 4 E) and com-
 
Table I.
 
Peptides Used in This Study
 
Peptide name Sequence
HA
 
PK
 
Y
 
VKQNTLKLAT
 
Biotin-HA (or bHA) Biotin-
 
GPK
 
Y
 
VKQNTLKLAT
 
Biotin-YHA (or bYHA) Biotin-
 
Y
 
VKQNTLKLAT
 
Biotin-6GC-Biotin (or b6GHA) Biotin-CGGGGGGPKYVKQNTLKLAT
HA-6GC-Biotin (or HA6Gb) PKYVKQNTLKLATGGGGGGC-Biotin
2G-HA GCGGPKYVKQNTLKLAT
6G-HA GCGGGGGGPKYVKQNTLKLAT
11-HA GCGGSGGGSGGSGPKYVKQNTLKLAT
HA-6G PKYVKQNTLKLATGGGGGGCG
CLIP PVSKMRMATPLLMQA
BCLIP Biotin-PVSKMRMATPLLMQA
CLIP-5PC PVSKMRMACPLLMQA
HA-5PC PKYVKQCTLKLAT
The residues that bind into the P1 specificity pocket of DR1 are shown in bold, and the cysteines used for linking to DM are underlined.
Figure 2. Assembly of the DM–peptide/DR1 complex. Cartoon dia-
gram of the four step synthetic strategy used to produce the DM–peptide/
DR1 complex in high yield. Presented here for the 6G-HA peptide (Ta-
ble I).
(Scheme I)178 Lateral Interaction Surfaces of HLA-DM with HLA-DR1
plexes between streptavidin and DR1 (Fig. 4, F–H) have
slow dissociation kinetics (half-lives of several hundred
minutes). The topmost band of each gel was scanned, and
the data were plotted as the fraction of complex remaining
versus incubation time (Fig. 5). It is worthwhile to note
that in all cases where DM was attached onto the NH2 ter-
minus of the peptide, complex dissociation followed single
exponential decay kinetics, indicating homogeneity in the
behavior of the complex and thus of the catalytic efficiency
of the attached DM.
The rapid dissociation kinetics observed require DM to
be attached to the peptide, as attachment of streptavidin did
not lead to a rate enhancement of such a magnitude. Disso-
ciation experiments were also performed using biotinylated
versions of the HA peptide (Table I) bound to streptavidin
through the attached biotin. The biotin was attached
through a 6 carbon linker to either the NH2- or the
COOH terminus of a peptide containing either a single
amino acid extension over the HA peptide (for the NH2
terminus) or a six amino acid extension (for the NH2- and
COOH terminus) as indicated in Table I. All streptavidin/
biotin-peptide/DR1 complexes dissociated slowly in the
presence of excess free peptide (Fig. 4, gels F-H). Thus, at-
Figure 3. Purification and analysis of the DM–peptide/DR1 complex.
(Top panel) DR1 preloaded with bYHA peptide was mixed with a four-
fold excess of streptavidin and then with a 1.5-fold excess of DM–pep-
tide. The mixture was incubated overnight and separated on Sephadex
S200 (Amersham Pharmacia Biotech). Positions of molecular weight stan-
dards (Bio-Rad Laboratories) are indicated with arrows bellow the chro-
matogram. (Inset) SDS-PAGE showing the composition of the purified
complex compared with equimolar amounts of DM and DR1 controls.
Samples were heated to 100 C for 5 min before loading. (Bottom panel)
Analysis of DM-pepitde/DR1 complex; SDS-PAGE (4–20%), nonreduc-
ing, nonboiled. Lane M, prestained molecular weight standards (Bio-Rad
Laboratories). Lane 1, previously purified DM–peptide/DR complex.
Lane 2, DR1/bYHA. Lane 3, purified DM. Lane 4, streptavidin. Lane 5,
fraction no. 43 (peak 1) from above. Lane 6, fraction no. 48 (peak 2).
Lane 7, fraction no. 53 (peak 3). Lane 8, fraction no. 61 (peak 4). Lane 9,
fraction no. 73 (peak 5). Note that the DM–peptide/DR1 complex is
SDS resistant (lane 1 or lane 5) when the sample is not boiled but falls
apart to the DM–peptide and DR1 components when the sample is
boiled (inset in chromatogram).
Figure 4. Time course of the disassembly of DM/DR1 and streptavi-
din/DR1 complexes followed by native gel electrophoresis. (Left col-
umn) Cartoon representations of complex tested. (Right column) Native
gel showing time points of the dissociation of each complex upon the ad-
dition of excess free HA peptide. In every case the top most band (or
bands) corresponds to the DM/DR complex (gels A–E) or the streptavi-
din/DR complex (gels F–H). Note the difference of dissociation rate be-
tween gels A–C and E, and the effect of the solution pH on the dissocia-
tion rate in gel D. Complex analyzed is indicated at the bottom of each
gel (“/” indicates a noncovalent interaction, where “ ” indicates a cova-
lent interaction. The NH2 terminus of the peptide is considered to be on
its left and the COOH terminus on its right).179 Stratikos et al.
tachment of DM, but not of any other protein, to the NH2
terminus of the peptide induced the enhanced dissociation.
Furthermore, the rate of dissociation of the NH2-termi-
nally linked DM/DR1 complex was found to depend on
pH in a manner similar to solution catalysis by DM. The
half-life of dissociation of the DM-6G-HA/DR1 complex
was found to be 90 min at pH 7.5 compared with 14 min
at pH 5.0 (Fig. 4 C), almost sixfold slower. This is in accor-
dance to previous reports that have identified pH 5.0 to be
the optimal for the catalytic activity of DM (which is also
the physiologically relevant pH, as it is the pH of the endo-
somes where DM exerts its physiological function; refer-
ence 8). These evidence taken together, strongly suggest
that the interaction of DM with DR1 in the NH2-termi-
nally tethered complexes is mechanistically similar to the
solution interaction.
Rapid dissociation of DM-peptide/DR1 complexes was
observed only when DM was attached to the NH2 termi-
nus of the peptide and not to the COOH terminus. When
DM was attached to the NH2 terminus of the peptide the
dissociation half-lives were between 12 and 14 min for a 6
or 11 amino acid linker and 37 min for a small 2 amino
acid linker. When DM was attached to the COOH termi-
nus of the peptide, the dissociation half-life was signifi-
cantly slower and depended on the concentration of the
complex itself in a manner similar to the dependence of
HA peptide dissociation from DR1 on the concentration
of soluble (untethered) DM as measured by an ELISA assay
(Fig. 6). Extrapolation of this dependence to infinite dilu-
tion (intercept with the y-axis in Fig. 6) should describe the
intrinsic (intramolecular) dissociation rate for this molecule
and was calculated to be 5   10 4 min 1 which corre-
sponds to a half-life of 1,386 min. This rate is two orders of
magnitude slower than the rate measured for the NH2-ter-
minally linked DM/DR complex and is very similar to the
dissociation rates of the streptavidin/DR1 complexes that
have half-lives of 591 to 825 min (Fig. 7). This suggests
that no DM-specific intramolecular effect is at work here.
Nevertheless, this rate is faster than the rate of release of
untethered peptide from DR1 which was calculated to be
3   10 5 min 1 by an ELISA assay described in Materials
and Methods (Fig. 6, filled diamonds), which indicates that
the tethering of a protein to any of the ends of the peptide
does present a small effect in the dissociation kinetics of the
peptide. However, this effect seems to be brought about by
either DM or streptavidin when tethered to the COOH
terminus of the peptide suggesting that it is not related to
the catalytic mechanism of DM. Furthermore the concen-
tration dependence of the COOH-terminally linked DM/
DR1 complex suggests that DM in this complex can cata-
lyze in trans the dissociation of peptides from other DR1
molecules but not from the one to which it is attached.
The ability of the COOH-terminally linked DM to cata-
lyze peptide exchange in trans is independently confirmed
by the finding that this complex can catalyze the dissocia-
tion of the DR1-bound peptide in a separate peptide ex-
change assay (fluorescence polarization assay as described in
Materials and Methods; data not shown) to an extent simi-
lar to catalysis by free, soluble DM. These observations sug-
gest that any acceleration of peptide release seen in the
COOH-terminally linked DM/DR1 complex compared
with the dissociation of the untethered peptide, is in part
due to nonspecific tethering effects and in part to intermo-
lecular catalysis by DM attached to other complexes. We
therefore conclude that when DM is tethered on DR1
through a linker attached to the COOH terminus of the
peptide, it is unable to interact with the tethered DR1 in a
normal catalytic manner, but the flexibility of the linker al-
lows it to interact with other DR1 molecules in solution.
Dissociation kinetics of NH2-terminally linked DM–
peptide/DR1 complexes appear to be independent of the
concentration of the complex, for the range of concentra-
tions examined, from 1 to 20  M. A 10-fold dilution of
the complex results in a similar degree of dissociation for a
Figure 5. Dissociation kinetics for DM/DR complexes. The intensity
of the topmost band of panels A, B, D, and E (see Fig. 4) was measured
and quantitated by densitometry and plotted versus time. The data were
fit to a single exponential decay model to produce the rate and the half-
life of dissociation.
Figure 6. Dependence of peptide dissociation from DR1 on DM con-
centration. Circles, peptide linked to DM through its NH2 terminus; trian-
gles, peptide linked to DM through its COOH terminus; diamonds, pep-
tide not linked to DM. For the case where the peptide is linked on DM
through its COOH terminus or not linked at all, the data were fit using a
simple linear model and the results of the fit are indicated in the graph. The
same was not possible for the case where the peptide is linked to DM
through its NH2 terminus since no clear dependence on the concentration
was found; in that case the drawn line is only given as a visual aid.180 Lateral Interaction Surfaces of HLA-DM with HLA-DR1
20 min incubation at 37 C (data not shown), whereas a 10-
fold dilution of a bimolecular reaction would be expected
to yield a 102 decrease in rate. The dissociation rates for a
series of DM-6G-HA/DR1 concentrations are shown in
Fig. 6 (filled circles). The y-axis intercept is the rate at infi-
nite dilution, where intermolecular effects are not observ-
able; the dissociation rate is virtually unchanged over the
concentrations tested with a y-axis intercept accounting of
almost, if not all, of its magnitude, indicating that the disso-
ciation is catalyzed predominantly intramolecularly. Al-
though some intermolecular (concentration dependent)
component similar in magnitude to the COOH-terminally
linked complex cannot be excluded by these experiments
its role in the dissociation of the NH2-terminally linked
complex is certainly secondary. The dominance of the con-
centration-dependent component in the dissociation of the
NH2-terminally linked DM/DR1 peptides strongly sug-
gests that it is an intramolecular event specific to DM (as
tethering a different protein does not lead to such an effect)
that leads to the fast kinetics observed.
Discussion
Four stable, tethered, DM/DR1 complexes were con-
structed and analyzed for enhanced peptide dissociation
rates from DR1. When DM was attached to the NH2 ter-
minus of the DR1-bound peptide we found rapid kinetics
of peptide dissociation. By contrast, when DM was at-
tached to the COOH terminus of the DR1-bound peptide
dissociation rates were slow. Similar slow dissociation ki-
netics were found when an unrelated protein, streptavidin,
was attached to either the NH2 or COOH terminus of the
peptide. Furthermore, the dissociation kinetics for the
complexes where DM was tethered to the NH2 terminus
of the peptide were found to be largely concentration inde-
pendent, suggesting that it is an intramolecular interaction
that is responsible for the rapid kinetics. The rapid kinetics
measured for the NH2-terminally linked complexes can be
attributed to the high local concentrations induced by the
covalent linkage. A simple calculation based on the spherical
volume that DM can occupy because of linker restrictions
(10, 30, and 45Å assumed linker lengths) indicates local
DM concentrations of 40, 1.5, and 0.5 mM, respectively.
Further restrictions because of steric clashes between the two
proteins would decrease the available volume that DM can
move into and increase the local concentration “visible” to
DR1 even further. Extrapolation to high DM concentra-
tions of the observed rates of peptide dissociation in solu-
tion assays using untethered DR1 and DM (Fig. 6, filled di-
amonds) shows that half-lives of dissociation of a few minutes,
Figure 7. Summary of half-
lives of intrinsic peptide dissocia-
tion for the DM–peptide/DR1
complexes, and Streptavidin/
peptide/DR1 constructs. Stan-
dard deviations indicated are a
result of 3–5 different measure-
ments. On the left is a cartoon
representation of the constructs,
where the solid thick line repre-
sents the peptide bound on DR1
and the thin line the linker be-
tween the peptide and DM or
Streptavidin. As the dissociation
of the complex where the pep-
tide is linked to DM through its
COOH terminus is dependent
on the concentration (Fig. 6),
the half-life shown here is calcu-
lated by extrapolating the con-
centration dependence to infi-
nite dilution (intercept with the
y-axis in Fig. 6). The half lives or
dissociation of the streptavidin/
DR1 complexes were estimated
from gels F–H of Fig. 4.181 Stratikos et al.
such as those observed in the tethered complexes, can be
expected at DM concentrations of  1 mM. Finally, the pH
of the solution was found to affect the rate of dissociation
of the tethered complexes in a manner similar to the effect
of pH on the catalytic ability of detergent solubilized DM
(8). These results, taken together, suggest that the interac-
tion between DM and DR1 in the NH2-terminally tethered
complexes is mechanistically similar to the normal interac-
tion in solution that leads to enhanced peptide dissociation.
For the three NH2-terminally tethered complexes stud-
ied, linker length seems to have only a marginal effect on
dissociation kinetics. A small increase in dissociation rate
was seen when the linker length was decreased from 11
amino acids to 6 amino acids, but this is much less than ex-
pected from the threefold increase in local concentration
(from 0.5 to 1.5 mM) based on the calculation above. Fur-
thermore, the dissociation rate decreased about threefold
when the linker length was decreased to only 2 amino acids
but still remained at least 10-fold higher than the rate ex-
pected by intermolecular catalysis at the concentrations
used in the experiment. This small decrease of the dissocia-
tion rate for the shortest linker, compared with the longer
linkers, is presumably due to some steric interference on
the DM/DR1 interaction imposed by the limited flexibil-
ity of a short connection. Overall, lack of clear correlation
between linker lengths and dissociation rates might indicate
a saturation of the catalytic activity of DM in very high
concentrations. This saturation might be attributed either
to KM saturation (the enzyme interacts with the substrate at
1:1 ratio) or to the possibility that DM accelerates only a
part of the peptide exchange pathway. In the latter case, the
overall peptide dissociation kinetics would become limited
by another step in the pathway when DM concentrations
are very high. Indeed, a recent study by Zarutskie et al.
(16) suggests that DM accelerates the equilibrium between
two peptide/DR1 conformations only, one of which is
able to release the peptide. It is not unreasonable to expect
that under very high DM concentrations, the interconver-
sion between those two conformations would become
faster than the peptide release and the observed rate would
then be the rate of peptide release from the rapidly releas-
ing conformation. This condition would, of course, signify
that in the DM-peptide/DR1 complexes described here,
the dissociation rates seen are the fastest possible rates of
HA peptide dissociation that can be induced by DM. Be-
cause of the large excess of free peptide used in the dissoci-
ation experiments, it is reasonable to assume that DM will
catalyze the dissociation of the complex it is part off only
once, and therefore the fastest rates calculated here (0.07
min 1) would also be the turnover number for DM cataly-
sis of peptide dissociation from DR1. These rates are more
than sufficient for peptide exchange in vivo and probably
represent an upper limit of DM catalysis in the cell, where
a high local concentration of DM is achieved by membrane
tethering and compartmentalization.
Fig. 8 presents a schematic representation of DM and
DR1 linked by a two-glycine linker through the NH2 ter-
minus of the HA peptide bound on DR1. Both proteins
are oriented in such a manner that the transmembrane tails
(not shown) would be located at the bottom of the picture.
Even with such a small linker length, it is reasonably easy to
position both proteins so that no steric clashes occur be-
tween them. The linker is modeled in a fully extended
form to reveal maximum degree of freedom that it can al-
Figure 8. Schematic model of HLA-DM
(left, red ribbon: chain A; cyan ribbon:
chain B) linked by a disulfide bond from
cysteine B46 (green sticks) to a cysteine at
the NH2 terminus of the HA peptide (red
sticks) bound on HLA-DR1 (right, blue
ribbon: chain A; yellow ribbon: chain B).
The linker from the NH2 terminus of the
peptide to the bonded cysteine is two gly-
cines (peptide 2G-HA, Table I) and is mod-
eled here in an extended conformation. Sol-
vent surfaces for both DM and DR1 are
shown in gray. Note the lack of clashes be-
tween DM and DR1, even for such a small
linker. Mutations on DR1 that have been
found to interfere with DM interaction are
indicated as green spheres (reference 19).
Tryptophans on DM that were previously
speculated to interact with DR1 are shown
in pink (reference 11). Figure was made
with PyMol (reference 28) using PDB coor-
dinate files 1HDM and 1DLH.182 Lateral Interaction Surfaces of HLA-DM with HLA-DR1
low in the interactions between DM and DR1. The find-
ing that the interaction between DM and DR1 seems to be
mechanistically the same compared with the untethered
proteins, even for such a short linker, imposes great restric-
tions in the possible surfaces of interactions on both pro-
teins. The requirement for DM to be tethered to the NH2
terminus of the peptide in order to catalyze its exchange ef-
ficiently in combination with the requirement of both pro-
teins to be tethered on the same membrane suggests that it
is the left lateral face of DR1 (as presented on Fig. 8) that
interacts with DM. This conclusion is in agreement with a
recent mutagenesis study (19), which identified mutations
that abolish DM/DR1 interactions as probed in cell assays
(the mutants identified in this study are indicated with
green spheres in Fig. 8). Furthermore, the short linker
identifies the surface of DM that interacts with DR1 as be-
ing the lateral face of DM that contains cysteine  46 (the
right side of DM as presented in Fig. 8). It has been previ-
ously speculated that two solvent-exposed tryptophans on
DM ( 62 and  120, shown in pink spheres in Fig. 8)
might reside in the interface of the DM/DR1 complex
(11). These tryptophans reside on the opposite face of DM
than cysteine  46, however, and it is thus virtually impossi-
ble to rotate DM so that they come in contact with DR1
while still satisfying the small linker restrictions. Our results
therefore suggest that the lateral face of DM that interacts
with DR1 is opposite from the one previously speculated.
The requirement for the proximity of cysteine  46 to the
NH2 terminus of the bound peptide also mechanistically
implicates the part of the binding groove of DR1 that ac-
commodates the NH2 terminus of the peptide in the DM/
DR1 interaction. The P1 pocket of DR1 (the pocket of
the binding groove that accommodates the tyrosine of the
HA peptide) is a very important binding determinant for
the peptide. Along with hydrogen bonds around it, is pos-
sibly a target region for DM (15, 24–26). A mechanism for
DM action that would be in agreement with the present
data would involve recognition and binding by DM of an
altered conformation of DR1 where the region that ac-
commodates the NH2 terminus of the peptide and the P1
side-chain is either partially unfolded or in a metastable
conformation that breaks some of the interactions with the
peptide. Interactions with the lateral face of DM, in the vi-
cinity of cysteine  46, could stabilize this conformation by
either substituting some of the interactions between pep-
tide and DR1 that were lost during the conformational
change or by creating new ones. This DR1 conformation
could be either the intermediate recognized before as a fast
peptide exchanger (14, 27) or a transition state leading to
that intermediate. In either case, stabilization of that tran-
sient conformation of DR1 by DM would result in an ap-
parently enhanced rate of peptide dissociation. Soluble,
tethered complexes where the DM/DR1 interaction is sat-
urated, like the ones presented here, in conjunction with
the knowledge of the interacting surfaces on both proteins,
can be powerful tools for “locking” the transient interac-
tion of DM with DR1. This would make the isolation of
the high energy conformational state of DR1 possible,
opening the way toward a detailed understanding of the
structural events of the mechanism of DM catalysis.
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